Therapeutic antibodies: successes, limitations and hopes for the future.
Reads0
Chats0
TLDR
An overview of the current state of the art of monoclonal antibodies is given and the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents are described.Abstract:
With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age as therapeutics, generating a market value of $11 billion in 2004, expected to reach $26 billion by 2010. While delivering interesting results in the treatment of several major diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are generating a wealth of useful information, for instance about associations of clinical responses with Fc receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics and tissue accessibility as well as impaired interactions with the immune system, and these deficiencies point to areas where additional research is needed. This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody-based therapeutic agents.
This article is part of a themed section on Vector Design and Drug Delivery. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009read more
Citations
More filters
Journal ArticleDOI
Introduction to current and future protein therapeutics: A protein engineering perspective
TL;DR: Two old concepts for improving antibodies, namely antibody-drug conjugates and bispecific antibodies, have advanced to the cusp of clinical success and several engineered protein scaffolds are in early clinical development and offer differences and some potential advantages over antibodies.
Journal ArticleDOI
Targeted therapy using nanotechnology: focus on cancer.
TL;DR: BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication.
Journal ArticleDOI
An overview of clinical and commercial impact of drug delivery systems
TL;DR: These examples provide strong evidence of the clinical and commercial impact of drug delivery systems, which have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others.
Journal ArticleDOI
Bispecific antibodies for cancer therapy
Patrick Chames,Daniel Baty +1 more
TL;DR: In this article, a review describes the most recent advances and clinical study results in the field of bispecific antibodies, a new class of molecules that might outshine conventional mAbs as cancer immunotherapeutics in a near future.
Journal ArticleDOI
How viruses hijack cell regulation.
TL;DR: The extensive mimicry of host protein short linear motifs (SLiMs) is revealed, showing how viruses hijack and manipulate these proteins utilising any achievable mechanism to commandeer so many diverse pathways and processes.
References
More filters
Journal ArticleDOI
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
Journal ArticleDOI
Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface
TL;DR: Foreign DNA fragments can be inserted into filamentous phage gene III to create a fusion protein with the foreign sequence in the middle that is incorporated into the virion, which retains infectivity and displays the foreign amino acids in immunologically accessible form.
Journal ArticleDOI
Phage antibodies: filamentous phage displaying antibody variable domains
TL;DR: It is shown that complete antibody V domains can be displayed on the surface of fd bacteriophage, that the phage bind specifically to antigen and that rare phage can be isolated after affinity chromatography.
Journal ArticleDOI
Naturally occurring antibodies devoid of light chains
Cécile Hamers-Casterman,Touriya Atarhouch,Serge Muyldermans,Gene E. Robinson,Hamers C,Songa Eb,Bendahman N,Raymond Hamers +7 more
TL;DR: The presence of considerable amounts of IgG-like material of Mr 100K in the serum of the camel, which is composed of heavy-chain dimers and devoid of light chains, but nevertheless have an extensive antigen-binding repertoire, opens new perspectives in the engineering of antibodies.
Journal ArticleDOI
Replacing the complementarity-determining regions in a human antibody with those from a mouse
TL;DR: This work substituted the CDRs from the heavy-chain variable region of mouse antibody B1–8, which binds the hapten NP-cap, for the corresponding CDRs of a human myeloma protein, to determine whether the antigen-binding site could be transplanted from one framework to another by grafting theCDRs.
Related Papers (5)
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more